Board Appointment

RNS Number : 4983R
Omega Diagnostics Group PLC
01 March 2019
 

 

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

 

Board Appointment

 

Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces the appointment of Jeremy Millard as Non-Executive Director to the Board with immediate effect, after a thorough search process.

 

The Board consider Jeremy to be independent and it is anticipated that he will, in due course, be appointed to the Audit and Remuneration Committees of the Company.

 

Jeremy has 20 years investment banking experience and was previously a partner at Smith Square Partners LLP where he provided strategic and corporate advice to clients in the science, technology and telecommunications sectors, prior to which he headed up the technology practice at Rothschild in London. Jeremy is currently a Non-Executive Director and chairman of the audit committee of AIM-listed Idox plc and a Non-Executive Director of AIM-listed Ilika Plc.

 

Bill Rhodes, Interim Non-Executive Chairman of the Company said: "We are delighted to have Jeremy join the Omega Board. With his relevant financial experience, familiarity with AIM-listed companies and his energy and enthusiasm for Omega, we feel confident that his appointment will bring immediate value to our Board and the Company in general."

 

The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies:

 

Mr Jeremy Howard Millard, age 47, is the brother-in-law of Richard Sneller, who has a substantial shareholding in the Company.

 

Current Directorships / Partnerships:

 

Idox plc

Ilika Plc

Blackbullion Limited

Iridium Corporate Finance Limited

 

Previous Directorships / Partnerships (held in the past five years)

 

Solar Communications Group Limited

Smith Square Partners LLP

 

Mr Millard does not currently hold any ordinary shares in the Company.  There are no other disclosures required in relation to Rule 17 or paragraph (g) of Schedule 2 of the AIM Rules for Companies.

 

 

 

Contacts: 

 

Omega Diagnostics Group PLC                         

Tel: 01259 763 030

Bill Rhodes, Interim Non-Executive Chairman

Colin King, Chief Executive                             

www.omegadiagnostics.com

Kieron Harbinson, Group Finance Director

 

 

 

finnCap Ltd                                              

Tel: 020 7220 0500

Geoff Nash/James Thompson(Corporate Finance)

 

Camille Gochez (ECM)

 

 

 

Walbrook PR Limited

Tel: 020 7933 8780 or omega@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOAPGUAAPUPBGQR
UK 100

Latest directors dealings